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Background. Severe acute respiratory syndrome (SARS) emerged as a human disease in 2002. Detailed phy-
logenetic analysis and epidemiologic studies have suggested that the SARS coronavirus (SARS-CoV) originated
from animals. The spike (S) glycoprotein has been identified as a major target of protective immunity and contains
3 regions that are targeted by neutralizing antibodies in the S1 and S2 domains. We previously characterized a
panel of neutralizing human monoclonal antibodies (MAbs), but the majority of epitopes recognized by the MAbs
remain unknown.
Methods. In the present study, we generated neutralization escape mutants and studied the effect of these
neutralization escape mutations on human and animal receptor usage as well as on in vitro and in vivo fitness.
Results. Distinct but partially overlapping sets of amino acids were identified that are critical to the binding
of MAbs with differential neutralization profiles. We also identified possible interactions between the S1 and S2
domains of the SARS-CoV S glycoprotein. Finally, we showed that escape from neutralization usually attenuates
SARS-CoV infection.
Conclusions. These data provide a mechanism for overcoming neutralization escape by use of broadly cross-
reactive cocktails of cross-neutralizing MAbs that recognize residues within the receptor-binding domain that are
critical for virus replication and virulence.
Severe acute respiratory syndrome coronavirus (SARS-
CoV) emerged in 2002/2003, infecting 18000 people
(associated fatality rate, 11%) [1]. SARS-CoV is a new
member of the virus family Coronaviridae that likely
emerged from strains that are continually circulating in
bats and other animals sold in live animal markets.
Thus, vaccines and therapeutics must target a hetero-
geneous pool of human and zoonotic variants to pre-
serve the public health.
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Several studies have shown that the SARS-CoV spike
(S) glycoprotein binds the angiotensin-converting en-
zyme 2 (ACE2) receptor and is a major component of
protective immunity. It contains 3 domains that are
targeted by neutralizing antibodies. In a previous study,
we generated and characterized a panel of 23 human
monoclonal antibodies (MAbs) that neutralized one or
multiple homologous and heterologous SARS-CoV S
glycoprotein variants [2]. These MAbs could be cate-
gorized into 6 different neutralization profiles, on the
basis of their ability to neutralize isogenic SARS-CoVs
bearing different human and zoonotic S glycoproteins
[2]. MAbs in groups I–III neutralized only human
strains, not zoonotic strains, and group VI was com-
prised of 4 MAbs that could neutralize all human and
zoonotic SARS-CoV strains tested in vitro and in vivo.
We demonstrated that these MAbs are attractive can-
didates for prophylactic treatment for the prevention
of laboratory-acquired infections as well as zoonotic
introductions [2]. However, escape from neutraliza-
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Table 1. Amino Acid Changes in the Severe Acute Respiratory
Syndrome Coronavirus (SARS-CoV) Spike Glycoprotein of Neu-
tralization Escape Mutants
Group,
monoclonal antibody Mutant 1 Mutant 2
I, S228.11 P462A P462H
II
S111.7 Y777D Y777D
S224.1 D463G Y777D
III
S3.1 L443R+Y777D L443R+Y777D
S127.6 D480Y D480Y
IV
S110.4 P462H P462H
S231.2 F460C F460C
VI
S109.8a T332I T332I
S230.15a L443R L443R
S215.17 P462H P462H
S227.14b K390Q K390E
a Amino acid changes were observed in neutralization escape mutants using
both icUrbani and icGZ02.
b Amino acid changes were observed in neutralization escape mutants using
icHC/SZ/61/03 only.
tion is a concern when developing these MAbs for therapeu-
tic purposes.
In the present study, we generated neutralization escape mu-
tants for a panel of 11 human MAbs. By use of structural
analysis and cross-neutralization assays, several distinct sets of
residues critical for neutralization were identified, as was a novel
site outside the receptor-binding domain (RBD) that is likely
involved in receptor interaction. In addition, the effects of these
mutations on the fitness and virulence of SARS-CoV were de-
termined in vitro and in vivo. These data identify subsets of
compatible cocktails of human MAbs that could serve as po-
tential therapeutic agents in laboratory exposures and/or in new
SARS-CoV outbreak settings.
MATERIALS AND METHODS
Viruses and cells. Recombinant icUrbani, icGZ02, and icHC/
SZ/61/03 and all derived escape mutants were propagated on
Vero E6 cells, as described elsewhere [2–3]. Delayed brain tu-
mor (DBT) cells stably expressing human (h) or civet (c) ACE2
were isolated by flow cytometry, as described elsewhere [3].
Growth curves were performed by inoculating Vero E6, DBT-
hACE2, and DBT-cACE2 cell cultures with the different viruses
at a multiplicity of infection (MOI) of 0.1 for 1 h, after which
the cells were overlaid with medium. Virus samples were ob-
tained at various time points after infection and stored at
70C until viral titers were determined by plaque assay, as
described elsewhere [2, 3].
Escape mutant analysis. Human MAbs against SARS-CoV
were generated as described elsewhere [4]. Neutralization-re-
sistant SARS-CoV mutants were generated as described else-
where [2]. In brief, pfu of icUrbani were incubated61 10
with 30 mg of a neutralizing MAb in 100 mL of media at 37C
for 1 h and then inoculated onto Vero E6 cells in the610
presence of the respective MAb at the same concentration. The
icHC/SZ/61/03 isolate was used to generate a neutralization
escape mutant for MAb S227.14, because several attempts to
generate escape mutants from this antibody with the use of
icUrbani and icGZ02 proved unsuccessful. The development
of cytopathic effect was monitored over 72 h, and progeny
viruses were harvested. MAb treatment was repeated 2 addi-
tional passages, passage 3 viruses were plaque purified in the
presence of MAb, and neutralization-resistant viruses were iso-
lated. Experiments were performed in duplicate, and the S gly-
coprotein gene of individual plaques from each experiment was
sequenced as described elsewhere [2]. The neutralization titers
of wild-type and MAb-resistant viruses were determined as de-
scribed elsewhere [2].
Computer modeling of RBD interactions with hACE2,
mACE2, and cACE2. The crystal structure coordinates of
SARS-CoV RBD interacting with the hACE2 receptor (Protein
Data Bank code 2AJF, chain A, and chain E) were used as a
template to map the location of the amino acid changes iden-
tified in the escape mutants.
Mouse infection. Female BALB/cBy mice (age, 12 months;
obtained from the National Institute on Aging) were intrana-
sally inoculated with pfu (icUrbani and its escape55.0 10
mutants) or pfu (icGZ02, icHC/SZ/61/03, and their re-510
spective escape mutants) of virus in a 500-mL volume, as de-
scribed elsewhere [2, 3, 5]. Mice were weighed daily, and at 4
or 5 days after infection, lungs were removed and frozen at
70C for determination of viral titers and histopathologic
changes, as described elsewhere [2, 3]. Experimental protocols
were reviewed and approved by the institutional animal care
and use committee at the University of North Carolina, Chapel
Hill.
RESULTS
Identification of amino acids critical for virus neutralization.
The icUrbani isolate was used to generate neutralization escape
mutants. On the basis of neutralization patterns across the
groups, we selected the group I MAb S228.11, 2 group II MAbs
(S111.7 and S224.17), 2 group III MAbs (S3.1 and S127.6), 2
group IV MAbs (S110.4 and S231.19), and all 4 group VI
broadly cross-neutralizing MAbs (S109.8, S215.17, S227.14, and
S230.15).
Of importance, 10 of 11 escape mutants contained single
amino acid changes, whereas the S3.1 escape mutant contained
2 amino acid changes at positions L443R and Y777D (Table
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1). The S109.8 escape mutant contained a single T332I change,
whereas the S230.15 escape mutant contained a L443R change
identical to what was previously shown using the S glycoprotein
from the early-phase icGZ02 isolate [2]. Of interest, several
MAb escape mutants from different neutralization groups had
amino acid changes in common (Table 1). The amino acid
change associated with neutralization escape from S127.6 was
a D480Y mutation, which was previously shown to decrease
the neutralization efficacy of the 80R MAb [6]. The group I
MAb S228.11, group IV MAb S110.4, and group VI MAb
S215.17 were all selected for escape mutant viruses with an
amino acid change at position 462. Finally, the generation of
a MAb neutralization escape variant using MAb S227.14 was
unsuccessful even after several attempts using both the icGZ02
[2] and the icUrbani isolate. However, with the use of the icHC/
SZ/61/03 isolate, 2 MAb neutralization escape mutants were
isolated, both of which contained a single amino acid mutation
at position 390, resulting in either a K390Q or K390E change.
Cross-neutralization of MAb neutralization escape mu-
tants. Identification of mutations associated with neutrali-
zation escape yielded a complex set of overlapping or nearly
overlapping mutations within the RBD, suggesting that escape
mutants selected with 1 antibody may provide resistance to
neutralization using other human MAbs. Consequently, we ex-
amined the cross-neutralization patterns of the escape mutants
by use of a panel of select MAbs (Figure 1).
The neutralization efficacy of the group I MAb S228.11 was
not only ablated by the P462A change present in its respec-
tive escape mutant, but it also could not neutralize viruses
containing mutations at L443R, F460C, P462H, and Y777D
(Figure 1A).
The neutralization efficacy of the 2 group II MAbs S111.7
and S224.1 was ablated for all other escape mutants, with the
exception of the T332I and D480Y mutants (Figure 1B).
The neutralization efficacy of the group III MAb S127.6 was
not affected by any amino acid change other than the D480Y
change that was selected for in its respective escape mutant. In
contrast, neutralization by the other group III MAb (S3.1) was
ablated by its respective escape mutations L443R and Y777D,
as well as by mutations F460C and P462H (Figure 1C).
MAb neutralization escape mutants generated against the
group IV MAbs (S110.4 and S231.2) contained 2 amino acid
changes located closely together (F460C and P462H). Not sur-
prisingly, the neutralization efficacies of these 2 MAbs were
very similar (Figure 1D).
Finally, the group VI MAbs were previously identified as
cross-neutralizing all human and zoonotic SARS-CoV isolates
unaffected by the amino acid changes naturally occurring dur-
ing the SARS-CoV epidemic [2]. MAbs S109.8 and S230.15
were only affected by the mutations that were present in their
respective neutralization escape mutants (eg, T332I and L443R)
(Figure 1E). Neutralization by S215.17 was affected by amino
acid changes L443R, F460C, and P462H but not by Y777D.
This was surprising, because MAb S110.4, which selected for
the identical P462H mutant, as well as MAb 228.11, which
selected for mutation P462A, were both affected by all 4 amino
acid changes (L443R, F460C, P462H, and Y777D). None of the
amino acid changes generated in the other escape mutants af-
fected the neutralization efficacy of S227.14.
Structural mapping of amino acids critical for neutrali-
zation. The structure of the SARS-CoV RBD complexed with
ACE2 was recently resolved, allowing us to map the locations
of the amino acid changes onto the RBD structure [7]. As
previously shown, amino acid 332 of the RBD is critical for
neutralization by MAb S109.8 and is located on the side of the
RBD in a loop that is not in direct contact with the receptor
ACE2 (Figure 2). Of interest, although MAbs S228.1, S224.17,
S3.1, S110.4, S231.9, S215.17, and S230.15 recognize distinct
antigenic groups based on their neutralizing profiles of isogenic
viruses with variant S glycoproteins, the locations of the amino
acid changes associated with the neutralization escape map were
within 4 a˚ngstroms of each other (Figure 2). Unfortunately the
location of the amino acid 777 alteration is downstream of the
RBD and upstream of the heptad repeat region; therefore, no
structural information was available. The D480Y change is
likely part of or is influencing presentation of a distinct epitope
recognized by MAb S127.6 and belonging to group III (Figure
2). Neutralization by the cross-neutralizing MAb S227.14 was
not affected by any of the mutations generated by the other
MAbs. The cross-neutralization data suggest that the amino
acid change K390Q/E associated with MAb neutralization es-
cape from S227.14 is uniquely separate from other escape mu-
tants (Figure 2).
Effect of S glycoprotein mutations on in vitro growth. The
Urbani S glycoprotein RBD is critical for docking and entry
and engages both hACE2 and cACE2 receptors [8, 9]. All but
one (D463G) of the neutralization escape mutations are either
directly adjacent (L443R) or within 4 a˚ngstroms (K390Q/E,
F460C, P462A/H, D463G, and D480Y) of key contact residue
sites encoded in the RBD at positions 436, 442, 473, 475, 479,
and 491 [7], which may interfere with binding to hACE2 or
cACE2. All neutralization escape viruses grew efficiently in Vero
E6 cells, reaching comparable peak titers of between and710
pfu/mL by 36 h after infection (Figure 3A). Replication of810
all viruses was delayed early in infection, as shown by a 1- to
2-log reduction in titer at 12 h after infection, compared with
the wild-type icUrbani, with the exception of the escape mutant
with a P462H change ( , by 2-way analysis of variance).P ! .05
A similar trend was seen in DBT cells expressing the hACE2
molecule (Figure 3B). Growth in DBT cells expressing the
cACE2 molecule was affected by all amino acid changes tested.
All viruses, with the exception of the F460C mutant, reached
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Figure 1. Neutralization efficacy of wild-type (WT) and neutralization escape mutants, as determined by use of a panel of neutralizing monoclonal
antibodies (MAbs). Representative MAbs from previously determined neutralization groups I (A), II (B), III (C), IV (D), and VI (E) were tested for their
ability to neutralize escape mutants [2]. Starting concentrations of MAbs were selected to show a reduction in neutralization of at least 6 dilutions
(1/32). The MAbs (starting concentrations) used were as follows: S228.1 (6 mg/mL), S111.7 (20 mg/mL), S224.1 (12 mg/mL), S3.1 (2 mg/mL), S127.6
(6 mg/mL), S110.4 (6 mg/mL), S231.2 (20 mg/mL), S215.17 (12 mg/mL), S109.8 (12 mg/mL), S227.14 (40 mg/mL), and S230.15 (12 mg/mL), as described
in Materials and Methods. MAb dilution at which 50% of the virus was neutralized is plotted. Error bars denote standard deviations. * ,P ! .05
compared with the icUrbani WT, by 2-way analysis of variance.
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Figure 2. Locations of neutralization escape variant mutations on the structure of the severe acute respiratory syndrome coronavirus (SARS-CoV)
receptor-binding domain (RBD). The location of residues critical for monoclonal antibody (MAb) neutralization is mapped onto the structure of the
SARS-CoV RBD (green) bound to its receptor angiotensin-converting enzyme 2 (ACE2) (blue). The amino acid changes associated with neutralization
escape from MAbs S228.11 (P462A/H), S224.1 (D463G), S3.1 (L443R), S127.6 (D480Y), S110.4 (P462H), S231.2 (F460C), S109.8 (T332I), S215.17 (P462H),
S227.14 (K390Q), and S230.15 (L443R) are shown in red. Amino acid Y491 (yellow) interacts with multiple residues on the ACE2 molecule.
peak titers of ∼ pfu/mL but were delayed 12 h after infection710
in replication, compared with icUrbani (Figure 3C). Of im-
portance, at 36 h after infection, the escape mutant virus with
a change at F460C showed a 2-log reduction in titer, compared
with icUrbani ( , by 2-way analysis of variance), sug-P ! .01
gesting that some escape mutations may alter virus fitness in
DBT cells expressing cACE2, potentially hampering virus per-
sistence in animal reservoirs.
Effect of S glycoprotein mutations on in vivo growth. Muta-
tions within the S glycoprotein of SARS-CoV can potentially
alter morbidity and mortality [3]. To test this possibility, 12-
month-old BALB/c mice were inoculated with either wild-type
icUrbani, icGZ02, or icHC/SZ/61/03 and each of their respec-
tive neutralization escape mutants. Under these conditions,
icUrbani resulted in a phenotype of ∼15% weight loss. Of in-
terest, although the Y777D change had an attenuating effect
on in vitro growth, no difference could be detected between
weight loss associated with the Y777D change and that asso-
ciated with the icUrbani isolate (Figure 4A). In contrast, neu-
tralization escape viruses with a D480Y or D463G change were
attenuated, with infected mice losing only 5% of their weight
by day 4 after infection, whereas viruses with a T332I, L443R,
F460C, or P462H amino acid change were completely atten-
uated in aged animals (Figure 4A). Viral titers in the lungs of
infected animals at day 5 after infection did not complete-
ly correlate with weight loss, as observed elsewhere [5]. The
P462H mutant virus grew to titers comparable to those of
icUrbani ( pfu/g) (Figure 4B). However, T332I, F460C, and610
L443R mutant virus titers were significantly reduced by 1, 2,
and 4 logs, respectively, compared with icUrbani titers. In agree-
ment with these data, the T332I and L443R mutations previ-
ously generated in icGZ02 [2] were also completely attenuated
in aged mice (data not shown). The K390E/Q mutants using
the icHC/SZ/61/03 strain associated with neutralization escape
from MAb S227.14 were completely attenuated in aged mice
with no loss of weight, whereas the wild-type icHC/SZ/61/03–
infected mice lost up to 20% of their weight by day 4 after
infection, and 2 of 5 mice died (Figure 4C). Of interest, no
difference in virus titers was observed at day 4 after infection
between the wild-type and neutralization escape mutants of
icHC/SZ/61/03 (Figure 4D).
In agreement with the observed weight loss in animals in-
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Figure 3. In vitro growth characteristics of wild-type (WT) and neu-
tralization escape mutant severe acute respiratory syndrome coronavirus
(SARS-CoV). Cultures of Vero E6 (A), delayed brain tumor (DBT)–human
angiotensin-converting enzyme 2 (ACE2) (B), and DBT–civet ACE2 (C) cells
were infected in duplicate with icUrbani WT (icUrbani WT) and neutral-
ization escape mutants T332I (S109.8), L443R (S230.15), L443R+Y777D
(S3.1), F460C (S231.2), P462H (S228.11, S110.4, and S215.17), D463G
(S224.1), D480Y (S127.6), and Y777D (S111.7) at a multiplicity of infection
(MOI) of 0.1, as described in Materials and Methods. Virus titers at
different time points were determined by a plaque assay using Vero E6
cells. Error bars denote standard deviations. * , compared with theP ! .01
icUrbani WT, by 2-way analysis of variance.
fected with the 2 lethal strains (icGZ02 and icHC/SZ/61/03),
by 4 days after infection, necrotizing bronchiolitis could be
observed in the lungs of these 12-month-old mice, with marked
loss and/or attenuation of the bronchiolar epithelium also
noted (Figure 5). These findings were accompanied by wide-
spread injury of the alveolar parenchyma. The histopathology
of this injury to the gas-exchange region of the lung consist-
ed of diffuse alveolar damage, interstitial edema, and hyaline
membrane formation. Of interest, animals infected with the neu-
tralization escape mutants generated against the cross-neutral-
izing MAbs S109.8, S230.15, and S227.14 had minimal or no
alveolitis present in the pulmonary parenchyma at 4 days after
infection, and no hyaline membranes were observed (Figure 5).
DISCUSSION
Neutralizing antibodies have been shown to be important in
recovery from and protection against infectious diseases [10].
However, the high mutation rate and heterogeneity of viruses
are major problems in the development of therapeutic MAbs,
especially MAbs against human viruses that emerge from het-
erogeneous pools circulating in animal reservoirs. To our
knowledge, the effects of escape mutations of human MAbs
after acute infection with human epidemic and zoonotic strains
of an emerging virus have not been rigorously investigated.
The goal of the present study was to characterize the anti-
body-targeting specificity of a large panel of neutralizing human
MAbs and identify residues that are critical to neutralization
of SARS-CoV through isolation of escape mutants. The effects
of these mutations on cross-neutralization, receptor usage, and
in vitro and in vivo replication were determined with the goal
of identifying compatible candidate cocktails of broad-spec-
trum neutralizing antibody therapeutics for the treatment of
future SARS-CoV epidemics. We identified the presence of sev-
eral critical residues associated with neutralization escape from
11 MAbs that showed overlap. In addition, we showed that
mutations associated with MAb neutralization escape also af-
fected the kinetics of replication in vitro and the degree of
pathogenicity in mice.
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Figure 4. Effect of neutralization escape on in vivo replication and morbidity. Weight loss (A and C ) and lung titer (B and D ) results for 12-month-
old female BALB/c mice infected with neutralization escape mutants T332I (S109.8), L443R (S230.15), L443R+Y777D (S3.1), F460C (S231.2), P462H
(S228.11, S110.4, and S215.17), D463G (S224.1), D480Y (S127.6), and Y777D (S111.7). Mice were intranasally inoculated with pfu of the55 10
icUrbani strain and its neutralization escape mutants (A and B ) or pfu of the icHC/SZ/61/03 strain and its neutralization escape mutants (C and510
D ) in 50 mL of phosphate-buffered saline (PBS). A and C, Body weights of infected mice were measured on a daily basis ( per group). Weightnp 5
changes are expressed as the mean percentage changes for infected animals relative to the initial weights at day 0. B and D, Lung tissues were
harvested from infected mice on day 5 (B) or 4 (D) after infection and were assayed for infectious virus as described in Materials and Methods.
Tissue samples from 5 mice were analyzed at each time point. Error bars denote standard deviations. * , compared with the icUrbani wild typeP ! .01
(WT), by 2-way analysis of variance. MAb, monoclonal antibody.
SARS-CoV is an excellent model system with which to study
the development of therapeutic antibodies against an emerg-
ing virus. SARS-CoV, like other RNA viruses, has a high muta-
tion rate, which is important for adapting to changing environ-
ments, such as those created by cross-species transmission [8,
11]. Using a panel of recombinant viruses bearing different S
glycoproteins from human epidemic and animal strains, We
previously characterized a panel of human MAbs and described
6 distinct neutralization profiles suggesting the presence of sev-
eral putative conformational epitopes [2].
In this study, we performed a detailed analysis of the residues
critical for neutralization by 11 different human MAbs that
differentially neutralized animal and human strains. Four of
these residues (at positions 443, 460, 462, and 463) map within
5 a˚ngstroms in the RBD structure and were associated with
escape from neutralization with MAbs from the 5 different
neutralization profiles, suggesting overlapping antigenic sites.
Although MAb-RBD cocrystallization studies will be necessary
to determine the complex architecture and orientation of the
RBD-neutralizing epitopes, our data suggest that subtle changes
in and around the escape mutation site can affect antibody
binding and neutralization. In fact, experimental and structural
data are available that support our hypothesis of overlapping
epitopes on the SARS-CoV RBD, recognized by MAbs that
display distinct neutralization profiles [12–16].
Escape mutant analysis has assisted in the identification of
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Figure 5. Lung pathologic findings in 12-month-old BALB/c mice infected with wild-type (WT) and escape mutants of icHC/SZ/61/03 and icGZ02
and killed 5 days after inoculation. Signs of inflammation and virus-induced lung pathologic findings are evident in WT-infected mice on day 4 after
infection with necrotizing bronchiolitis. This was accompanied by widespread injury of the alveolar parenchyma consisting of diffuse acute alveolitis,
interstitial edema, congestion in the alveolar septa and around small blood vessels, scattered microthrombi in septal capillaries, and hyaline membrane
formation. In contrast, mice infected with icGZ02 or icHC/SZ/61/03 neutralization escape mutants showed no inflammation or hyaline membrane
formation.
antigenic sites for several viruses, including rhinovirus and
SARS-CoV [17–21], and it previously has been used to identify
the importance of P462 in the neutralization of SARS-CoV by
MAb CR3014 [21]. The structures of 2 MAbs complexed with
the SARS-CoV RBD have been described elsewhere [15, 16].
The MAb m396 mainly recognizes a 10-residue (482–491) loop
that protrudes from the RBD surface and competes with
S230.15 for binding to the RBD [22]. Because the S230.15
epitope includes the amino acid 443 residue that is distant from
the m396 epitope, competition likely occurs through steric hin-
drance between the 2 MAbs. The 80R MAb was found to in-
teract with 29 residues between 426 and 492 on the SARS-CoV
RBD. The D480 residue was of particular interest, because mu-
tations at this residue completely abolished binding to 80R. Of
interest, a mutation at residue 480 was also found to affect the
neutralization efficacy of one of the group III MAbs described
in the present study (S127.6), suggesting that these MAbs rec-
ognize an identical or overlapping epitope, as hypothesized
elsewhere [18].
The cross-neutralization data suggested an association be-
tween residue Y777 and1 group of residues at locations L443,
F460, P462, and D463. Recently, another study [17] demon-
strated an association between amino acid changes in the S1
and S2 domains of SARS-CoV, affecting neutralization. Cur-
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rently, the structure of the complete SARS-CoV S glycoprotein
bound to its receptor ACE2 has not been elucidated, and, there-
fore, mapping the effects of long-range amino acid changes
outside the RBD on the global S glycoprotein structure is not
possible. However, these data suggest that the S1 and S2 do-
mains of the S glycoprotein communicate with the RBD and
may even interact physically in the higher-order structure of
the S glycoprotein, as has been shown for other coronaviruses
[23, 24]. Of importance, other domains outside the RBD have
been targeted by neutralizing MAbs, including amino acids
130–140 and HR-2 [25]. Although it is not clear whether these
domains are associated with the RBD, our previous work also
implicated changes at positions 77 and 244 as affecting neu-
tralization of MAbs S132 and S228.11 after RBD binding [2].
Although the generation of neutralization escape mutants
can be a very helpful tool in the identification of the residues
critical for neutralization, it generally compromises the use of
these single MAbs as prophylaxis or treatment. However, ami-
no acid changes within the SARS-CoV S glycoprotein not on-
ly affect neutralization but also have dramatic effects on the
fitness and virulence of the virus.
In a previous study, we showed that a single mutation at
position 577 or 578 outside the RBD in some zoonotic S gly-
coprotein genes was associated with the development of cy-
topathic effect in cell culture [3]. In addition, the introduction
of 6 amino acid changes in the SARS-CoV S glycoprotein re-
sulted in lethal infection in aged mice [3].
In the current study, we showed a clear effect on in vitro
replication by several different escape amino acid mutations.
Because many of the escape mutants grew to similar titers
after an initial delay in growth, the observed mutations likely
mediate a reduced affinity of RBD for the hACE2 receptor,
resulting in a delay in entry. Some escape mutants also in-
fluenced the ability of virus to grow in cells expressing cACE2,
suggesting that these escape viruses may be inefficiently main-
tained in animal reservoirs.
Encouragingly, many escape mutations also had a clear effect
on in vivo pathogenesis using an aged mouse model. Although
a mutation at residue 777 did not affect in vivo pathogenesis,
all other mutations either partially or completely attenuated
SARS-CoV infection in aged mice. A decrease in virulence of
neutralization escape mutants has also been observed with H5
and H9 influenza viruses and has coincided with reduced af-
finity of the mutant HA for its receptor [26, 27]. Given the
delayed growth of many of these escape mutants on cells ex-
pressing hACE2, we anticipate that they would be attenuated
in humans. In addition, we were unsuccessful in isolating mu-
tants resistant to the sequential generation of escape variants
using different MAbs. Several attempts to rescue virus from
escape mutants that were incubated with other neutralizing
MAbs in the presence of the original MAb were unsuccessful
(unpublished data). Therefore a cocktail of potent, broadly
cross-neutralizing MAbs, like the one described elsewhere [2],
will overcome neutralization escape and provide protection
from disease after laboratory accidents, zoonotic introductions,
or focal outbreaks of disease [18, 28].
In conclusion, our data support the hypothesis that multiple
overlapping neutralizing epitopes exist within the RBD of the
SARS-CoV S glycoprotein, with clusters of escape mutations
affecting neutralization by MAbs with different neutralization
profiles. A residue at location 777, associated with epitopes
involving residues 443, 460, 462, and 463, suggests long-range
interactions within the SARS-CoV S glycoprotein. We showed
that neutralization escape comes with the cost of reduced viral
fitness and propose the development of a broadly cross-neu-
tralizing MAb cocktail to overcome the generation of escape
variants. We propose that a cocktail of MAbs S227.14 and
S230.15 is particularly robust, because these MAbs individually
neutralize a broad panel of human and zoonotic SARS-CoV
variants and select for escape mutations at different sites in the
RBD, and because escape mutants are severely attenuated in
aged animals.
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